[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Manuel Ricardo Espinoza-Gutarra\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100622252","assessing-the-incidence-of-transplant-associated-thrombotic-microangiopathy-ta-tma-in-adult-patients-undergoing-allogeneic-stem-cell-transplant-sct-100622252",false,"NCT07381205","Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)","Prospective Evaluation of Transplant Associated Thrombotic Microangiopathy (TA-TMA) Markers in a High-risk Cohort of Adults Undergoing Allogeneic Stem Cell Transplantation (SCT)","Inclusion Criteria:\n\n* Inclusion Criteria\n\n  1. Adult male or female, age ≥18\n  2. Undergoing allogeneic SCT at UAB for any indication and any donor source.\n  3. For patients in cohort 1: Patients deemed high-risk for developing high-risk TA-TMA as stated by any of the following criteria\\*:\n\n     1. BMI \\> 35\\[42\\]\n     2. Mismatched donor (either Haploidentical or Mismatched Unrelated donor)\\[18, 29\\]\n     3. Non-Malignant Transplant Indication (Severe Aplastic Anemia or Sickle Cell Disease)\\[18, 43\\]\n     4. Acute Lymphoblastic Leukemia (any kind)\\[18, 31\\]\n     5. African American, Hispanic, Asian or Native American Ethnicity \\[44\\]\n     6. Myeloablative Conditioning Regimen\\[18\\]\n     7. Pre-Existing Renal Disease\\*\\* (defined as any of the following: 24 Hr Creatinine Clearance \\\u003C60, baseline serum creatinine \\> 1.2, 24 hr proteinuria \\>150mg or random spot urine Protein Creatinine ratio \\> 150mg\u002Fg)\\[20, 45\\]\n     8. TBI-containing conditioning regimen \\>400cGy \\[46\\]\n     9. Prior Autologous or Allogeneic SCT\\[45\\]\n\n        * \\*Some of these criteria have been adapted from pediatric literature due to a higher number of publications in that setting and in cases where the adult data is lacking or contradictory.\n        * \\*\\*Proteinuria thresholds are obtained from KDIGO guidelines and include moderate and severe levels of proteinuria\\[47\\].\n  4. Females of childbearing potential must have a negative urine or serum pregnancy test prior to enrollment.\n  5. For patients in cohort 2: Patients who develop GVHD with any of the following characteristics and were not included in cohort 1\n\n     1. Grade III-IV aGVHD, or SR-aGVHD of any grade, whichever occurs first\n     2. Moderate to Severe cGVHD or SR-cGVHD of any grade, whichever occurs first\n  6. For patients in cohort 3: Patients included in either cohort 1 or 2 who are diagnosed with TA-TMA and receive eculizumab\n\nExclusion Criteria:\n\n* Exclusion Criteria\n\n  1. Any other active malignancy requiring treatment or with expected survival ≤1 year.\n  2. Patients with psychiatric illness or social situations that would limit compliance with the study requirements.","ALL","18 Years",{"count":19,"type":20},85,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the incidence of Transplant Associated Thrombotich Microangiopathy (TA-TMA), which is a known but underreported complication of Allogeneic Stem Cell Transplant (SCT). The main question it aims to answer is:\n\nWhat is the incidence of TA-TMA in adults undergoing SCT? How does TA-TMA diagnosis impact survival and other outcomes? Patients undergoing SCT will be eligible for this study, which will consist of collection of biological samples and standard clinical follow up.",[24,25],"Transplant Associated Microangiopathy TAM","Transplant Complication",[27,28],"Transplant Associated Thrombotic Microangiopathy","Allogeneic Stem Cell Transplant","NOT_YET_RECRUITING","2026-03-09",{"date":32,"type":33},"2026-03-11","ACTUAL",{"date":35,"type":20},"2026-07-01",{"date":37,"type":20},"2028-10",{"name":39,"class":40},"Manuel Ricardo Espinoza-Gutarra","OTHER",""]